BioXcel Therapeutics, Inc. BTAI on Wednesday released topline exploratory efficacy data from the SERENITY At-Home Pivotal Phase 3 safety trial, which demonstrated that BXCL501 had continued effects and consistent benefit with repeat dosing.The trial in the home setting evaluated a 120 mcg dose of BXCL501, the company’s proprietary, sublingual film formulation of dexmedetomidine, Igalmi, for agitation associated with bipolar disorders or schizophrenia.Recently, BioXcel reported topline safety results and is ...